Latest News for: mdcx

Edit

Multi-Class Drone Missions Managed by a Single Operator in JADC2 Demonstration

Drone Life 18 Dec 2025
Integrated MDCX and XTEND XOS enable a single operator to manage complex, ...
Edit

Disrupting a $6 Billion Skin Cancer Market: The Small-Cap Biotech (MDCX) Advancing a Non-Surgical Patch

GetNews 04 Dec 2025
MDCX) emerges as a compelling small-cap opportunity ... Why MDCX Is Worth Watching ... MDCX) is advancing global clinical programs, integrating strategic acquisitions, and preparing for potential regulatory catalysts.
Edit

Medicus Pharma Ltd. (NASDAQ: MDCX) and the Patch That Could End Repetitive Cancer Surgeries

GetNews 05 Nov 2025
MDCX). MDCX is a clinical-stage biotechnology company advancing late-stage programs in oncology and urology ... RazorPitch has been retained and compensated by Medicus Pharma to assist in the production and distribution of content related to MDCX.
Edit

Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP)

GetNews 30 Oct 2025
MDCX) has quietly positioned itself as one of the more compelling small-cap biotech stories of 2025 ... That kind of financial discipline, combined with a focus on near-term catalysts, positions MDCX well for a period of potential revaluation.
Edit

4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA)

GetNews 23 Oct 2025
MDCX) is drawing attention as one of the more aggressive small-cap biotech names moving through late-stage clinical development with multiple catalysts lined up into 2026 ... of content related to MDCX.
Edit

4 Diagnostic Stocks Targeting 25%+ Annual Growth in a $20B Market (MDCX, ILMN, EXAS, GH)

GetNews 16 Oct 2025
MDCX) is quietly shaping up to be one of the more compelling names in small-cap biotech ... For investors looking for early-stage biotech exposure with meaningful upside potential, MDCX is a name worth watching.
Edit

Medicus Pharma (Nasdaq: MDCX) Nears Surgery-Free Breakthrough in Oncology

GetNews 10 Oct 2025
MDCX) is working to close ... MDCX), this acquisition expands the company’s reach into two multibillion-dollar markets while building a more diversified late-stage pipeline ... MDCX) is not chasing the next incremental advance.
Edit

Medicus Pharma (Nasdaq: MDCX) Bringing Scar-Free, Outpatient Treatment to an $8 Billion Cancer Market

GetNews 02 Oct 2025
MDCX) is stepping into that gap ... MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets ... content related to MDCX.
Edit

Biotech Stocks Positioned to Transform Treatment With Next-Gen Therapeutics (MDCX, PRTC, RANI, INO)

GetNews 26 Sep 2025
MDCX) is a clinical-stage biotech company working on disruptive approaches to cancer and urologic disease ... Together, these assets place MDCX at the intersection of oncology, drug delivery, and urology, with billions in potential market opportunity.
Edit

4 Biotech Stocks at the Cutting Edge of Drug Delivery (MDCX, RNA, NBTX, ARWR)

GetNews 18 Sep 2025
MDCX) is steadily building momentum in the race to reshape drug delivery ... RazorPitch has been retained and compensated by Medicus Pharma to assist in the production and distribution of content related to MDCX.
  • 1

Article Search

tools
×
×
×
×